Fulgent Genetics, Inc.
FLGT Nasdaq· Services-Medical Laboratories
Last close · Oct 27, 2026
$20.70
KIRA · Stoqly’s AI analyst, in plain words
- Fulgent Genetics, Inc. had $323M of revenue in fiscal 2025, up 13.8% on the year before. Over five years, revenue changed −5.2% a year on average.
- Its operating margin was −28.2%, down 2.2 pts: of every 100 in sales, about −28 is left after running the business.
- Fulgent Genetics, Inc. lost $60.5M in fiscal 2025.
- Free cash flow was −$124M in fiscal 2025, −38.5% of revenue.
- Fulgent Genetics, Inc. returned $10.9M to shareholders in fiscal 2025. The diluted share count rose 1.8%.
Market cap
$580M
P/E
—
Revenue
$323M
Net income
−$60.5M
Free cash flow
−$124M
Operating margin
−28.2%
Fulgent Genetics, Inc. in 30 seconds · fiscal 2025
Are sales growing?
+13.8%
Yes. Sales grew 13.8% last year.
Does it make a profit?
−18.8%
No. It lost money last year.
Does profit turn into cash?
−38.5%
No. It spent more cash than it brought in.
How healthy are the accounts?
3 / 8
Weak. It passes 3 of 8 health tests.
What Fulgent Genetics, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Feb 27, 2026
- Legal name
- Fulgent Genetics, Inc.
- CIK
- 0001674930
Fulgent Genetics, Inc. · FLGT
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $993M | $619M | $289M | $283M | $323M |
| Revenue growth | 135.4% | −37.6% | −53.3% | −2.0% | 13.8% |
| Gross margin | 78.3% | 59.3% | 36.1% | 37.8% | 40.6% |
| Operating margin | 68.1% | 28.8% | −67.6% | −26.1% | −28.2% |
| Net income | $507M | $143M | −$168M | −$42.7M | −$60.5M |
| Net margin | 51.1% | 23.2% | −58.0% | −15.1% | −18.8% |
| Cash | |||||
| Cash from operations | $539M | $254M | $27.0M | $21.1M | −$102M |
| Capital expenditure | $23.8M | $18.8M | $22.2M | $40.3M | $22.6M |
| Free cash flow | $515M | $235M | $4.8M | −$19.3M | −$124M |
| FCF margin | 51.9% | 37.9% | 1.7% | −6.8% | −38.5% |
| Share buybacks | — | $74.3M | $25.1M | $0.2M | $10.9M |
| Share count change | 28.8% | −0.0% | −3.8% | 1.5% | 1.8% |
| Debt and strength | |||||
| Cash and short-term investments | $165M | $79.5M | $97.5M | $258M | $336M |
| Shareholders' equity | $1.2B | $1.3B | $1.1B | $1.1B | $1.1B |
| Current ratio | 5.8x | 7.1x | 7.0x | 4.9x | 6.5x |
| Interest coverage | 5,777.4x | 516.0x | −400.7x | — | −1,214.6x |
| Returns and quality | |||||
| Return on equity | 58.7% | 11.8% | −14.0% | −3.8% | −5.4% |
| Return on tangible equity | 47.3% | 14.7% | −17.3% | −4.4% | −6.3% |
| Piotroski F-score | 6 | 5 | 3 | 4 | 3 |
| Altman Z'' | 18.6 | 16.8 | 14.6 | 15.8 | 14.4 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.7M
2 insiders
Of sales under plans
0%
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Fulgent Genetics, Inc. · FLGT
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $20.70 a share, the company is worth $580M.
Source: SEC EDGAR XBRL filings (CIK 0001674930). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.